Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Relatlimab + Nivolumab SC in Advanced Tumors
NCT04112498Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2019
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relatlimab in solid tumor, melanoma, non-small cell lung cancer (NSCLC) and 5 more, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed serum concentration at 60 days, Time of maximum observed serum concentration at 60 days and 7 more. Started Oct 2019; status: completed.
02
Drugs
relatlimab
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)gastric adenocarcinomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04112498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04112498.